3.72
+0.49(+15.17%)
Currency In USD
| Previous Close | 3.23 |
| Open | 3.26 |
| Day High | 3.85 |
| Day Low | 3.26 |
| 52-Week High | 4.05 |
| 52-Week Low | 1.34 |
| Volume | 1.29M |
| Average Volume | 442,652 |
| Market Cap | 122.89M |
| PE | -4.83 |
| EPS | -0.77 |
| Moving Average 50 Days | 2.64 |
| Moving Average 200 Days | 2.24 |
| Change | 0.49 |
If you invested $1000 in Immix Biopharma, Inc. (IMMX) since IPO date, it would be worth $1,013.62 as of November 13, 2025 at a share price of $3.72. Whereas If you bought $1000 worth of Immix Biopharma, Inc. (IMMX) shares 3 years ago, it would be worth $3,611.65 as of November 13, 2025 at a share price of $3.72.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
GlobeNewswire Inc.
Yesterday at 1:45 PM GMT
- Former Chimerix (CMRX, acquired by Jazz for $935 million) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic MODEYSO® - - Rare disease commercial veteran Mr. Grabow to lead Immix’s U.S. launch
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
GlobeNewswire Inc.
Nov 03, 2025 1:45 PM GMT
- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced tha
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
GlobeNewswire Inc.
Oct 14, 2025 12:45 PM GMT
LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host institutional investor